37 documents

Read All
16:51 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Data raise possibility BAN2401 primarily benefits Alzheimer’s subgroup

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented detailed data for BAN2401 that allayed some concerns that the placebo arm had driven a false efficacy signal in the Phase II Study 201 to treat...
Read More
23:09 , Oct 25, 2018 |  BC Extra  |  Clinical News

Data raise possibility BAN2401 primarily benefits Alzheimer’s subgroup

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented detailed data for BAN2401 Thursday that allayed some concerns that the placebo arm had driven a false efficacy signal in the Phase II Study 201 to...
Read More
20:50 , Oct 23, 2018 |  BC Extra  |  Company News

Biogen halts vixotrigine development in painful lumbosacral radiculopathy

Biogen Inc. (NASDAQ:BIIB) will halt development of vixotrigine (BIIB074) for a pain indication after a Phase IIb miss disclosed in the biotech's 3Q18 earnings. Biogen beat total revenue and earnings estimates for the quarter, with...
Read More
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
Read More
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
Read More
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
Read More
18:53 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Biogen, Eisai's elenbecestat reduces plaques, slows AD progression in Phase II

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) reported data from the Phase II Study 202 for their β-site APP-cleaving enzyme 1 (BACE1) inhibitor elenbecestat (E2609) showing that the therapy reduced amyloid plaques and slowed...
Read More
16:50 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Biogen, Eisai's BAN2401 slows cognitive decline by 30% in Phase II Alzheimer's trial

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 at the Alzheimer's Association International Conference showing that the anti-β-amyloid therapy slowed cognitive decline by as much as 30%. However,...
Read More
21:56 , Jul 26, 2018 |  BC Extra  |  Company News

Biogen, Eisai AD readout leads to stock dive

Biogen Inc. (NASDAQ:BIIB) sank $39.09 (10%) to $344.74 on Thursday after reporting detailed data from a Phase II trial of Alzheimer's disease candidate BAN2401. Although the data showed that the anti-β amyloid therapy slowed cognitive...
Read More
23:50 , Jul 25, 2018 |  BC Extra  |  Clinical News

BAN2401 slows cognitive decline by 30% in Phase II Alzheimer's trial

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 Wednesday at the Alzheimer's Association International Conference showing that the anti-β amyloid therapy slowed cognitive decline by as much as...
Read More